June 18, 2020 / 1:16 PM / 20 days ago

BRIEF-Avacta Updates On Affimer Therapy For COVID-19 Infection

June 18 (Reuters) - Avacta Group PLC:

* AVACTA GROUP PLC - UPDATE ON AFFIMER® THERAPY FOR COVID-19 INFECTION

* AVACTA - INFECTIVITY ASSAYS SHOW THAT AFFIMER REAGENTS PREVENT INFECTION OF HUMAN CELLS BY A SARS-COV-2 MODEL VIRUS

* AVACTA - INITIAL PHASE OF COLLABORATION SHOW “NEUTRALISING” AFFIMER REAGENTS PREVENT SARS-COV-2 MODEL VIRUS FROM ENTERING HUMAN CELLS

* AVACTA GROUP PLC - INITIAL PHASE OF A COLLABORATION SHOWING THAT THESE “NEUTRALISING” AFFIMER REAGENTS PROVIDE A POTENTIAL THERAPY FOR COVID-19 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below